Evaluating prostate cancer using FAPI PET/MRI scans

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to investigate how FAPI (fibroblast activation protein inhibitor) binds to specific cells in tumor tissue to enhance the diagnosis and monitoring of prostate cancer. Participants will undergo two PET/MRI scans during separate research visits, each lasting up to 2.5 hours. The study focuses on patients with known prostate cancer and aims to gather data on non-osseous, non-nodal metastases to improve clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Able and willing to provide informed consent
* Known diagnosis of prostate cancer
* Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET
* Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.
* Willing and able to undergo PET/MRI as part of this research

Exclusion Criteria:

* Unable or unwilling to provide informed consent
* Contraindication(s) to or inability to undergo PET/MRI
* Participants for whom PET/MRI will delay timely delivery of treatment
* Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:
* Have their own prescription for the medication
* The informed consent process is conducted prior to the self-administration of this medication
* Come to the research visit with a driver

Where it's running

• University of Wisconsin
  Madison, Wisconsin, United States Recruiting

Study contacts

• Principal investigator: Ali Pirasteh, MD — University of Wisconsin, Madison
• Study coordinator: Radiology Studies
• Email: Radstudy@uwhealth.org
• Phone: 608-282-8349

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PSMA-targeted fluorescent dye OTL78 to guide prostate cancer surgery

  This study tests whether the PSMA-targeted fluorescent dye OTL78, used with near-infrared imaging, can help doctors better find and remove prostate cancer tissue during surgery in men with confirmed prostate cancer.

  Recruiting at 2 sites Phase 2/3 Indiana University · Carmel, Indiana and 1 other locations · NCT07725523

• Using PSMA PET with MRI to watch for prostate cancer returning after focal therapy

  We will try adding a PSMA PET scan to routine MRI follow-up to see if it finds prostate cancer coming back sooner in men who had focal (partial gland) therapy.

  Recruiting University of Chicago · Chicago, Illinois · NCT07115914

• Mini-tumors to guide treatment for aggressive prostate cancer

  We will grow tiny, patient-derived mini-tumors in the lab to test which treatments work best for men with aggressive or metastatic prostate cancer.

  Recruiting Maastricht Radiation Oncology · Heerlen, Limburg and 2 other locations · NCT07004582

• Combining radiotherapy or surgery with intense hormone therapy for advanced prostate cancer

  This study is testing if combining surgery or radiation with strong hormone therapy can help men with newly diagnosed advanced prostate cancer feel better and live longer.

  Recruiting Phase 2 The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Nanjing, Jiangsu · NCT06992232

• SRT for bone and lymph node metastases in advanced prostate cancer

  This trial tests whether treating multiple metastatic lesions with stereotactic radiotherapy can prolong pain control and prevent complications in men with advanced, treatment‑refractory prostate cancer.

  Recruiting Institut Cancerologie de l'Ouest · Saint-Herblain · NCT06978296

• High-resolution XEOS AURA 10 PET-CT imaging of removed tumor tissue to compare with pathology and outcomes

  This registry will test whether high-resolution PET-CT scans of removed tumor tissue using the XEOS AURA 10 match pathology results and help guide care and long-term outcomes for adults having cancer surgery.

  Recruiting at 4 sites XEOS Medical · Aalst and 4 other locations · NCT06970275

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.